India Pharma Outlook Team | Monday, 28 March 2022
The Telangana government on Sunday said US-based complex generic and specialty drugs player, Slayback Pharma, will be capitalizing $ 20 million towards expansion of its operations in Hyderabad over the next three years.
This would include setting up of a cGMP lab and a developing facility in the city. The company has already invested around $30 million in the last five years. The declaration by the company was made during a meeting of the US visit of a delegation led by Telangana IT and industries
minister KT Rama Rao with Ajay Singh, founder & CEO, Slayback Pharma. The startyp, that commenced its operations in Hyderabad in 2017 with a total headcount of around 35, has grown to three facilities with a total headcount of 106. In 2018, it set up a R&D lab in Genome Valley with an injectable formulation development lab, OSD (oral solid dosage) formulation development lab and analytical development lab.
Commenting on the development, KTR said, “ I am delighted to note the phenomenal growth of Slayback Pharma in Hyderabad and its extension plans. I am confident that the vibrant ecosystem of Hyderabad will continue to support the company’s growth aspirations and I am happy to see many such life sciences corporations scaling new heights.” Besides, the delegation also met private equity firm, Advent International, that has venture plans for Hyderabad’s life sciences and pharma companies.
, CDSCO.jpg)
